Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AETHER: Allogeneic hMSCs in Idiopathic Pulmonary Fibrosis
NCT02013700Phase 1Terminated
- Start
- Nov 2013
- Primary completion
- Dec 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of laromestrocel in idiopathic pulmonary fibrosis (IPF) (4 arms). Primary endpoint: Safety and Tolerability of Intravenous Allo hMSCs at 1 month. Started Nov 2013; status: terminated.
02
Drugs
laromestrocel
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02013700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013700.